Triamcinolone
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1957
- First approval year
- 1957
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Triamcinolone
- Molecular weight
- 394.44
- Structure (SMILES)
- C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
- aristocort
- Aristocort
- delphicort
- Delphicort
- kenacort
- Kenacort
- triamcinolone
- Triamcinolone
- volon
- Volon
- 20mg triamcinolone
- 40mg triamcinolone
- 80mg triamcinolone
- 9 fluoro 11 beta 16 alpha 17 21 tetrahydroxypregna 1 4 diene 3 20 dione
- 9-FLUORO-11,BETA,,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE
- nsc 13397
- NSC-13397
- pregna 1 4 diene 3 20 dione 9 fluoro 11 16 17 21 tetrahydroxy 11 beta 16 alpha
- PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,16,17,21-TETRAHYDROXY-, (11.BETA.,16.ALPHA.)
- steroid (triamcinolone)
- Topical Triamcinolone
- triamcinolona
- Triamcinolona
- triamcinolone
- Triamcinolone
- Triamcinolone (20 g)
- Triamcinolone (Optional)
- TRIAMCINOLONE [EP MONOGRAPH]
- TRIAMCINOLONE [GREEN BOOK]
- TRIAMCINOLONE [HSDB]
- triamcinolone [INN]
- TRIAMCINOLONE [JAN]
- TRIAMCINOLONE [MART.]
- TRIAMCINOLONE [MI]
- TRIAMCINOLONE [ORANGE BOOK]
And 26 more, listed on the interactive page.
- CAS registry numbers
- 124-94-7
- ChEMBL ID
- CHEMBL1451
- InChIKey
- GFNANZIMVAIWHM-OBYCQNJPSA-N
- PubChem compound IDs
- 31307
- RxNorm IDs (RxCUI)
- 10759
- FDA ingredient codes (UNII)
- 1ZK20VI6TY
- A01AC01
- C05AA12
- D07AB09
- D07XB02
- H02AB08
- R01AD11
- R03BA06
- S01BA05
Sources for recorded values
- Applicant
- ASTELLAS
- Approval date
- 3 Dec 1957
- Application number
- NDA011161
- First in class
- No
- Orphan designation
- No
- Availability
- discontinued
- Pharmacology name
- triamcinolone
- Type
- Synthetic organic
- Drug name stem
- -olone
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Median affinity
- 7.7
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Pancreatitis, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000342
- Subject identifier
- D050500
- Condition
- Psoriasis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Skin Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Macular Degeneration
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001365
- Subject identifier
- D008268
- Condition
- Diabetic Retinopathy
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003770
- Subject identifier
- D003930
- Condition
- Lung Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003818
- Subject identifier
- D008171
- Condition
- Pain
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Melanosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003963
- Subject identifier
- D008548
- Condition
- Alopecia Areata
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004192
- Subject identifier
- D000506
- Condition
- Vitiligo
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004208
- Subject identifier
- D014820
- Condition
- Keloid
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004212
- Subject identifier
- D007627
- Condition
- Vascular Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004264
- Subject identifier
- D014652
- Condition
- Osteoarthritis, Knee
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004616
- Subject identifier
- D020370
- Condition
- Wet Macular Degeneration
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004683
- Subject identifier
- D057135
- Condition
- Eye Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005752
- Subject identifier
- D005128
- Condition
- Neuralgia
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0005762
- Subject identifier
- D009437
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005854
- Subject identifier
- D006255
- Condition
- Sinusitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0007486
- Subject identifier
- D012852
- Condition
- Lichen Planus, Oral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008517
- Subject identifier
- D017676
- Condition
- Hemorrhoids
- Highest recorded phase
- 4
- Condition identifier
- EFO:0009552
- Subject identifier
- D006484
- Condition
- Nasal Polyps
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000391
- Subject identifier
- D009298
- Condition
- Acneiform Eruptions
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000662
- Subject identifier
- D017486
And 15 more, listed on the interactive page.
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000342
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000701
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003046
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003770
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003818
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003874
- Condition identifier
- EFO_0003894
- Condition identifier
- EFO_0003907
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003917
- Condition identifier
- EFO_0003963
- Condition identifier
- EFO_0003963
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004192
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004208
- Condition identifier
- EFO_0004212
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004264
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004352
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004599
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004616
- Condition identifier
- EFO_0004683
- Condition identifier
- EFO_0005752
- Condition identifier
- EFO_0005752
- Highest recorded phase
- 4
And 176 more, listed on the interactive page.
- Event
- adrenal insufficiency
- Reports
- 262
- Reporting signal score
- 778.247
- Event
- adrenal suppression
- Reports
- 58
- Reporting signal score
- 221.409
- Event
- antibody test positive
- Reports
- 63
- Reporting signal score
- 213.853
- Event
- arthritis
- Reports
- 116
- Reporting signal score
- 102.432
- Event
- arthritis bacterial
- Reports
- 45
- Reporting signal score
- 90.321
- Event
- atrophy
- Reports
- 30
- Reporting signal score
- 81.3322
- Event
- blindness
- Reports
- 85
- Reporting signal score
- 97.1255
- Event
- body height below normal
- Reports
- 101
- Reporting signal score
- 465.514
- Event
- bone density decreased
- Reports
- 98
- Reporting signal score
- 253.552
- Event
- c-reactive protein increased
- Reports
- 100
- Reporting signal score
- 95.1868
- Event
- cataract
- Reports
- 99
- Reporting signal score
- 103.97
- Event
- chorioretinopathy
- Reports
- 55
- Reporting signal score
- 159.372
- Event
- condition aggravated
- Reports
- 252
- Reporting signal score
- 85.8601
- Event
- cushing's syndrome
- Reports
- 226
- Reporting signal score
- 813.885
- Event
- cushingoid
- Reports
- 65
- Reporting signal score
- 173.983
- Event
- cytomegalovirus chorioretinitis
- Reports
- 54
- Reporting signal score
- 164.798
- Event
- drug interaction
- Reports
- 265
- Reporting signal score
- 129.767
- Event
- drug intolerance
- Reports
- 99
- Reporting signal score
- 136.209
- Event
- drug specific antibody
- Reports
- 44
- Reporting signal score
- 154.67
- Event
- endophthalmitis
- Reports
- 153
- Reporting signal score
- 444.816
- Event
- eye infection toxoplasmal
- Reports
- 66
- Reporting signal score
- 303.335
- Event
- eye inflammation
- Reports
- 54
- Reporting signal score
- 113.517
- Event
- glaucoma
- Reports
- 74
- Reporting signal score
- 122.246
- Event
- human antichimeric antibody positive
- Reports
- 93
- Reporting signal score
- 509.451
- Event
- hypopyon
- Reports
- 28
- Reporting signal score
- 82.0388
And 36 more, listed on the interactive page.
- NCT00000569
- NCT00105027
- NCT00370266
- NCT00532142
- NCT00805064
- NCT00371111
- NCT02556424
- NCT00132925
- NCT00211419
- NCT00370630
- NCT00398866
- NCT05992883
- NCT00597766
- NCT00623766
- NCT00658736
- NCT01318590
- NCT00717652
- NCT00849537
- NCT00930189
- NCT01073995
- NCT01222871
- NCT01330524
- NCT01688362
- NCT01797432
- NCT01906944
And 20 more, listed on the interactive page.
- Dose
- 0.025%, 0.1%, 0.5%
- How often
- Two to four times daily or two to three times daily
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 4
- Polar surface area
- 115.06
- Calculated partition coefficient (ALogP)
- 0.62
- Calculated partition coefficient (XLogP)
- 1.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 28
- Molecular formula
- C21H27FO6
- Monoisotopic mass
- 394.17916674
- Natural product
- No
- Recorded assays
- 2,642
- Active assays
- 59
- Confirmatory
- Other
- Screening
- Summary
- Anti-Inflammatory Agents
- Glucocorticoids
These details could not be displayed.
Related records
Trials (200)
- "Platelet-Rich Plasma" Epidural Injection an Emerging Strategy in Lumbar Disc Herniation
- 10% Dextrose Versus Triamcinolone Injections After Pulsed Radiofrequency for Herniated Nucleus Pulposus
- A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
- A Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks
- A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema
- A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema
- A Prospective Study of EUS Guided Celiac Block
- A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors
- A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache
- A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
- A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
- A Study of Ponsegromab in People With Heart Failure
- A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption
- A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
- A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Approved for (4)
- Eye disorder
- Hemorrhoid
- Obstructive lung disease
- Skin disorder
In development for (31)
- Acneiform dermatitis Phase 2
- Age-related macular degeneration Phase 1
- Allergic rhinitis Phase 3
- Alopecia areata Phase 2
- Anterior ischemic optic neuropathy Phase 1
- Atopic eczema Phase 2
- Chronic obstructive pulmonary disease Phase 3
- Chronic pancreatitis Phase 3
- Corneal edema Phase 3
- Diabetic macular edema Phase 3
- Diabetic retinopathy Phase 1
- Keloid Phase 3
- Lichen planus, oral Phase 2
- Lung disorder Phase 3
- Macular retinal edema Phase 3
- Melanoma Phase 2
- Nasal cavity polyp Phase 1
- Neuralgia Early phase 1
- Orbital pseudotumor Phase 3
- Osteoarthritis Phase 3
Other linked conditions (5)
Targets (1)
- NR3C1 Glucocorticoid receptor agonist